ANEW MEDICAL Receives Notification of Issuance of Alzheimer’s Gene Therapy Patent and Claims by the European Patent Organization (EPO)
NEW YORK, Dec. 26, 2022
NEW YORK, Dec. 26, 2022 /PRNewswire/ — ANEW MEDICAL, INC., a technology and medical product holding company (OTC: LEAS) (“ANEW” or the “Company”) received notification by the EPO of its intention to grant a patent titled “Secreted Splicing Variant of Mammalian Klotho as a Medicament for Cognition and Behaviour Impairments” to Universitat Autonomous De Barcelona (UAB) and Institucio Catalana De Recerca Estudis Avancats (ICREA) of Barcelona, Spain. The technology was licensed on an exclusive worldwide basis in 2022 from UAB and ICREA by ANEW MEDICAL.
The patent provides 20 years of patent protection for several ANEW medical product candidates from competition in diseases such as Alzheimer’s diseases, Parkinson’s disease, Huntington’s diseases, Lou Gehrig’s disease (“ALS”), Dementia with Lewy bodies, Creutzfeldt-Jakob disease, Multiple Sclerosis, Ataxia telangiectasia, post-stroke dementia, post-trauma dementia, senile dementia, and craniocerebral trauma.
“The Company’s proprietary secreted α-Klotho protein and lead gene therapy construct exhibits robust and prolonged bioactivity in several animal models of Alzheimer’s disease and the results support the development of this new approach to treat cognitive impairment and other age-related diseases” stated Dr. Joseph Sinkule, the CEO and Founder of ANEW.
About ANEW MEDICAL, INC. – ANEW MEDICAL (OTC: LEAS) is a technology and medical product holding company focused on the development of therapeutics and diagnostics for a broad range of life-threatening disease indications. The Company has offices in the US and in Spain.
For information on ANEW MEDICAL, INC. please visit www.anewmeds.com or contact the Company at email@example.com.
Forward-Looking Statements – This press release contains forward-looking statements. All statements other than statements of historical facts are “forward-looking statements,” including those relating to future events. In some cases, forward-looking statements can be identified by terminology such as “plan”, “expect”, “anticipate”, “may”, “might”, “will”, “should”, “project”, “believe”, “estimate”, “predict”, “potential”, “intend”, or “continue”, or other words or terms of similar meaning. These statements include, without limitation, statements related to research, plans for future development, and the potential of a drug development candidate. Forward-looking statements are based on our current plans, objectives, estimates, expectations and intentions, and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such statements as a results of these risks and uncertainties, which may include risks and uncertainties of COVID and its impact on the Company’s clinical plans, product development and clinical success thereof, the uncertainties of regulatory approvals, manufacturing and supply risks, and other risks and uncertainties affecting the Company and its research and development programs as set forth in its SEC filings. Risks and uncertainties of which the Company is not currently aware may also affect the Company’s forward-looking statements. The Company undertakes no obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations or other circumstances that exist after the date as of which these forward-looking statements were made.
View original content to download multimedia:https://www.prnewswire.com/news-releases/anew-medical-receives-notification-of-issuance-of-alzheimers-gene-therapy-patent-and-claims-by-the-european-patent-organization-epo-301709879.html
SOURCE ANEW MEDICAL, INC.